Trials / Completed
CompletedNCT01790217
An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
GERMAN TARCEVA NON-INTERVENTIONAL STUDY in 1st Line Treatment of NSCLC EGFR Mutation Positive Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in first-line therapy in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. Eligible patients, for whom the treating physician has decided to initiate treatment with Tarceva according to the local label will be followed for 18 months.
Conditions
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2013-02-13
- Last updated
- 2016-11-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01790217. Inclusion in this directory is not an endorsement.